Purple Biotech Adjusts ADS Ratio to 1:2000
Purple Biotech announced that it intends to change the ratio of american depositary shares to its ordinary shares from the current ADS ratio of one ADS representing 200 ordinary shares, to a new ADS ratio of one ADS representing 2,000 ordinary shares. For the company's ADS holders, the ADS ratio change will have the same effect as a one-for-ten reverse ADS split. The ADS ratio change is expected to become effective at the beginning of trading on or about March 2. The primary purpose of the ADS ratio change is to enable the company to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Trade with 70% Backtested Accuracy
Analyst Views on PPBT
No data
About PPBT
About the author
Purple Biotech Adjusts ADS Ratio to Meet Nasdaq Compliance
- ADS Ratio Change: Purple Biotech announced a change in the ADS ratio from 1:200 to 1:2000, effective March 2, 2026, aimed at meeting Nasdaq's compliance requirement for a minimum bid price of $1.00, thus mitigating delisting risks.
- Reverse Split Impact: The ADS ratio change effectively acts as a one-for-ten reverse split, which, while not affecting the company's ordinary shares, is expected to increase the trading price of the ADSs, enhancing their suitability for trading on Nasdaq.
- Simplified Holder Actions: Registered holders of certificated ADSs will be required to surrender their ADSs to the depositary bank for cancellation, while holders of uncertificated ADSs will have their shares automatically exchanged, reducing operational complexity for investors.
- Future Growth Potential: With a focus on developing innovative immunotherapies, the ADS ratio change is anticipated to attract more investor interest in Purple Biotech's clinical-stage cancer products, further strengthening the company's market position in tumor immunotherapy.
Purple Biotech Reports Significant Anti-Tumor Activity of CAPTN-3 Platform at ESMO IO 2025
- Significant Anti-Tumor Activity: Purple Biotech's CAPTN-3 platform demonstrates substantial anti-tumor activity through its tri-specific antibodies IM1240 and IM1305 across different tumor antigens, particularly showing strong efficacy in PD-1 resistant models, indicating the platform's potential applicability in various solid tumors.
- Key Role of NKG2A Arm: Transcriptomic analysis of approximately 11,000 TCGA samples reveals a strong correlation between NKG2A expression and tumor expression of 5T4 or TROP2, supporting the inclusion of the NKG2A arm in CAPTN-3 designs, which enhances anti-cancer immune activity, especially in PD-1 resistant patient-derived samples.
- Platform Adaptability Validation: The new candidate IM1305, targeting TROP2, shows high-affinity binding (EC₅₀ ~2 nM) and potent PBMC-mediated tumor cell killing across multiple tumor types, further validating the adaptability and broad application potential of the CAPTN-3 platform, particularly in triple-negative breast cancer.
- Future Development Roadmap: Purple Biotech plans to advance CAPTN-3 toward IND-enabling studies in 2026, demonstrating the company's strategic commitment to addressing tumor immune evasion and drug resistance, aiming to capture market opportunities through continuous innovation.
Purple Biotech Reports New Anti-Tumor Data from CAPTN-3 Platform
- Significant Anti-Tumor Activity: Purple Biotech's CAPTN-3 platform demonstrates substantial anti-tumor activity through its tri-specific antibodies IM1240 and IM1305 across different tumor antigens, particularly showing strong apoptosis induction in PD-1 resistant models, indicating the platform's potential applicability in various solid tumors.
- Key Role of NKG2A Arm: Transcriptomic analysis of approximately 11,000 TCGA samples reveals a strong correlation between NKG2A expression and the expression of tumor antigens 5T4 or TROP2, supporting the inclusion of the NKG2A arm in CAPTN-3 designs, thereby enhancing anti-cancer immune activity, especially in PD-1 resistant patient-derived samples.
- Platform Adaptability Validation: The new candidate IM1305 exhibits high affinity binding to both TROP2 and NKG2A, achieving potent tumor cell killing at low concentrations (EC₅₀ 1-5 pM) across multiple tumor types, further validating the adaptability and broad application potential of the CAPTN-3 platform.
- Future Development Roadmap: Purple Biotech plans to advance the CAPTN-3 platform toward IND-enabling studies in 2026, with CEO Gil Efron emphasizing that the platform's multifunctional mechanisms will help overcome immune evasion challenges in solid tumor treatments, showcasing strong market prospects.
Three Penny Stocks to Keep an Eye on as of October 30, 2025
Penny Stocks to Watch: Cambium Networks, Purple Biotech, and Ernexa Therapeutics are highlighted as top penny stocks to monitor on October 30, 2025, based on their significant Dollar Volume and stock price movements.
Cambium Networks: The company experienced a Dollar Volume of $1.54 billion and a stock price increase of 377% following its integration with SpaceX's Starlink, enhancing its telecommunications solutions.
Purple Biotech: This clinical-stage biopharmaceutical company saw a Dollar Volume of $438.91 million and an 81% stock price surge after announcing a production milestone for its cancer treatment antibody, IM1240.
Ernexa Therapeutics: With a Dollar Volume of $375.25 million and a nearly 41% stock price rise, Ernexa is advancing its lead cell therapy for ovarian cancer through a partnership with Cellipont Bioservices.
Alphabet Shares Rise Approximately 8%; Check Out 20 Stocks Making Moves in Premarket Trading
Alphabet Inc. Financial Results: Alphabet Inc. reported third-quarter revenue of $102.35 billion and earnings of $2.87 per share, both exceeding analyst expectations, leading to a 7.8% increase in share price during pre-market trading.
Pre-Market Stock Gainers: Several stocks saw significant gains in pre-market trading, including VCI Global Limited (+110%), Cambium Networks Corporation (+87.8%), and Guardant Health, Inc. (+22.3%), following positive financial announcements.
Pre-Market Stock Losers: Notable declines were observed in stocks such as CERo Therapeutics Holdings, which fell 75.8% due to a Nasdaq delisting determination, and Aditxt, which dropped 38.8% after announcing a reverse stock split.
Market Overview: The article highlights various stocks' performance in pre-market trading, showcasing both significant gainers and losers, reflecting the volatility and reactions to recent financial results and announcements.
Dow Rises by 250 Points; Verizon Reports Mixed Results for Q3
U.S. Stock Market Performance: U.S. stocks rose this morning, with the Dow Jones gaining approximately 250 points, while the NASDAQ and S&P 500 also saw increases of 0.65% and 0.33%, respectively.
Sector Movements: Information technology stocks experienced a significant rise of 1.4%, whereas real estate stocks fell by 1.1% during trading.
Verizon's Financial Results: Verizon Communications reported mixed third-quarter results, with a 1.5% year-over-year revenue growth of $33.8 billion, falling short of analyst expectations, but exceeding EPS estimates.
Notable Stock Movements: Cambium Networks' shares surged 209% after a significant announcement, while Advent Technologies saw a 51% drop in its stock price following disappointing guidance.
Purple Biotech Adjusts ADS Ratio to Meet Nasdaq Compliance
- ADS Ratio Change: Purple Biotech announced a change in the ADS ratio from 1:200 to 1:2000, effective March 2, 2026, aimed at meeting Nasdaq's compliance requirement for a minimum bid price of $1.00, thus mitigating delisting risks.
- Reverse Split Impact: The ADS ratio change effectively acts as a one-for-ten reverse split, which, while not affecting the company's ordinary shares, is expected to increase the trading price of the ADSs, enhancing their suitability for trading on Nasdaq.
- Simplified Holder Actions: Registered holders of certificated ADSs will be required to surrender their ADSs to the depositary bank for cancellation, while holders of uncertificated ADSs will have their shares automatically exchanged, reducing operational complexity for investors.
- Future Growth Potential: With a focus on developing innovative immunotherapies, the ADS ratio change is anticipated to attract more investor interest in Purple Biotech's clinical-stage cancer products, further strengthening the company's market position in tumor immunotherapy.
Purple Biotech Reports Significant Anti-Tumor Activity of CAPTN-3 Platform at ESMO IO 2025
- Significant Anti-Tumor Activity: Purple Biotech's CAPTN-3 platform demonstrates substantial anti-tumor activity through its tri-specific antibodies IM1240 and IM1305 across different tumor antigens, particularly showing strong efficacy in PD-1 resistant models, indicating the platform's potential applicability in various solid tumors.
- Key Role of NKG2A Arm: Transcriptomic analysis of approximately 11,000 TCGA samples reveals a strong correlation between NKG2A expression and tumor expression of 5T4 or TROP2, supporting the inclusion of the NKG2A arm in CAPTN-3 designs, which enhances anti-cancer immune activity, especially in PD-1 resistant patient-derived samples.
- Platform Adaptability Validation: The new candidate IM1305, targeting TROP2, shows high-affinity binding (EC₅₀ ~2 nM) and potent PBMC-mediated tumor cell killing across multiple tumor types, further validating the adaptability and broad application potential of the CAPTN-3 platform, particularly in triple-negative breast cancer.
- Future Development Roadmap: Purple Biotech plans to advance CAPTN-3 toward IND-enabling studies in 2026, demonstrating the company's strategic commitment to addressing tumor immune evasion and drug resistance, aiming to capture market opportunities through continuous innovation.
Purple Biotech Reports New Anti-Tumor Data from CAPTN-3 Platform
- Significant Anti-Tumor Activity: Purple Biotech's CAPTN-3 platform demonstrates substantial anti-tumor activity through its tri-specific antibodies IM1240 and IM1305 across different tumor antigens, particularly showing strong apoptosis induction in PD-1 resistant models, indicating the platform's potential applicability in various solid tumors.
- Key Role of NKG2A Arm: Transcriptomic analysis of approximately 11,000 TCGA samples reveals a strong correlation between NKG2A expression and the expression of tumor antigens 5T4 or TROP2, supporting the inclusion of the NKG2A arm in CAPTN-3 designs, thereby enhancing anti-cancer immune activity, especially in PD-1 resistant patient-derived samples.
- Platform Adaptability Validation: The new candidate IM1305 exhibits high affinity binding to both TROP2 and NKG2A, achieving potent tumor cell killing at low concentrations (EC₅₀ 1-5 pM) across multiple tumor types, further validating the adaptability and broad application potential of the CAPTN-3 platform.
- Future Development Roadmap: Purple Biotech plans to advance the CAPTN-3 platform toward IND-enabling studies in 2026, with CEO Gil Efron emphasizing that the platform's multifunctional mechanisms will help overcome immune evasion challenges in solid tumor treatments, showcasing strong market prospects.
Three Penny Stocks to Keep an Eye on as of October 30, 2025
Penny Stocks to Watch: Cambium Networks, Purple Biotech, and Ernexa Therapeutics are highlighted as top penny stocks to monitor on October 30, 2025, based on their significant Dollar Volume and stock price movements.
Cambium Networks: The company experienced a Dollar Volume of $1.54 billion and a stock price increase of 377% following its integration with SpaceX's Starlink, enhancing its telecommunications solutions.
Purple Biotech: This clinical-stage biopharmaceutical company saw a Dollar Volume of $438.91 million and an 81% stock price surge after announcing a production milestone for its cancer treatment antibody, IM1240.
Ernexa Therapeutics: With a Dollar Volume of $375.25 million and a nearly 41% stock price rise, Ernexa is advancing its lead cell therapy for ovarian cancer through a partnership with Cellipont Bioservices.
Alphabet Shares Rise Approximately 8%; Check Out 20 Stocks Making Moves in Premarket Trading
Alphabet Inc. Financial Results: Alphabet Inc. reported third-quarter revenue of $102.35 billion and earnings of $2.87 per share, both exceeding analyst expectations, leading to a 7.8% increase in share price during pre-market trading.
Pre-Market Stock Gainers: Several stocks saw significant gains in pre-market trading, including VCI Global Limited (+110%), Cambium Networks Corporation (+87.8%), and Guardant Health, Inc. (+22.3%), following positive financial announcements.
Pre-Market Stock Losers: Notable declines were observed in stocks such as CERo Therapeutics Holdings, which fell 75.8% due to a Nasdaq delisting determination, and Aditxt, which dropped 38.8% after announcing a reverse stock split.
Market Overview: The article highlights various stocks' performance in pre-market trading, showcasing both significant gainers and losers, reflecting the volatility and reactions to recent financial results and announcements.
Dow Rises by 250 Points; Verizon Reports Mixed Results for Q3
U.S. Stock Market Performance: U.S. stocks rose this morning, with the Dow Jones gaining approximately 250 points, while the NASDAQ and S&P 500 also saw increases of 0.65% and 0.33%, respectively.
Sector Movements: Information technology stocks experienced a significant rise of 1.4%, whereas real estate stocks fell by 1.1% during trading.
Verizon's Financial Results: Verizon Communications reported mixed third-quarter results, with a 1.5% year-over-year revenue growth of $33.8 billion, falling short of analyst expectations, but exceeding EPS estimates.
Notable Stock Movements: Cambium Networks' shares surged 209% after a significant announcement, while Advent Technologies saw a 51% drop in its stock price following disappointing guidance.
